Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma
ABSTRACT Despite increasing reports of hepatitis B virus (HBV) reactivation in hematological malignancies, its incidence, and risk factors are still obscure. The aim of this study was to clarify the frequency and risk factors of HBV reactivation in hepatitis B surface antigen (HBsAg) undetectable pa...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2013-11, Vol.85 (11), p.1900-1906 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1906 |
|---|---|
| container_issue | 11 |
| container_start_page | 1900 |
| container_title | Journal of medical virology |
| container_volume | 85 |
| creator | Matsui, Takeshi Kang, Jong-Hon Nojima, Masanori Tomonari, Akiko Aoki, Hironori Yamazaki, Hajime Yane, Kei Tsuji, Kunihiko Andoh, Seisho Andoh, Sachiko Sakai, Hajime Maemori, Masayo Maguchi, Hiroyuki Tanaka, Yasuhito |
| description | ABSTRACT
Despite increasing reports of hepatitis B virus (HBV) reactivation in hematological malignancies, its incidence, and risk factors are still obscure. The aim of this study was to clarify the frequency and risk factors of HBV reactivation in hepatitis B surface antigen (HBsAg) undetectable patients with malignant lymphoma or multiple myeloma, during or after chemotherapy. A total of 109 patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma were enrolled in this study. Anti‐hepatitis B surface (anti‐HBs) and anti‐hepatitis B core (anti‐HBc) were checked before treatment, and HBV DNA in sera was quantified monthly during and after chemotherapy. Out of 109 patients, 42 (38.5%) had anti‐HBs and 59 (54.1%) had anti‐HBc. Among the 59 anti‐HBc positive patients, four patients (4/59, 6.8%) showed HBV reactivation during 20.5 median follow‐up months. In all four patients with HBV reactivation, peripheral lymphocyte counts before chemotherapy were lower than those without HBV reactivation (P = 0.033). HBV reactivation occurred during and after chemotherapy containing rituximab for non‐Hodgkin lymphoma. Four patients, who had HBV reactivation, did not develop de novo hepatitis due to HBV reactivation and were able to undergo chemotherapy against malignant lymphoma as scheduled. Monitoring of HBV DNA in sera is useful for the early diagnosis of HBV reactivation, and preemptive therapy is an useful alternative to prevent hepatitis due to HBV reactivation. Patients must be monitored periodically for HBV‐DNA levels during and after chemotherapy. J Med. Virol. 85:1900–1906, 2013. © 2013 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/jmv.23694 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1434030749</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3055737051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4544-a63a9900b08d1487d821162d350c8e434b4718a24e60beee6399b1553863196e3</originalsourceid><addsrcrecordid>eNqN0c1u1DAQB_AIgei2cOAFkCWEBIe0_ooTH7sVbUEtSFDo0XKSya6XJA62syVvwGPj_WiRkJA42Rr9ZsbWP0leEHxMMKYnq259TJmQ_FEyI1iKVOKcPE5mmHCRCkGyg-TQ-xXGuJCUPk0OKJNU4ILOkl-fQVfBrHUwtke2QUsY4j0Yj-ZobdzokenRpgR98OjOhCUa-xoCVEGXLaDLuT9dbEtuYU2_QNUSOhuW4PQwocY61OnWLHrdB9RO3bC0nUab6tgGM8QB3QRtrD1LnjS69fB8fx4lX8_f3ZxdplefLt6fnV6lFc84T7VgWkqMS1zUhBd5XVBCBK1ZhqsCOOMlz0mhKQeBSwAQTMqSZBkrBCNSADtK3uzmDs7-GMEH1RlfQdvqHuzoFYkzMMM5l_9BaZHnlJIs0ld_0ZUdXR8_slVEsDzfqLc7VTnrvYNGDc502k2KYLVJUsUk1TbJaF_uJ45lB_WDvI8ugtd7oH2l28bpvjL-j4svw5SK6E527s60MP17o_pw_e1-dbrrMD7Az4cO7b4rkbM8U7cfLxSe3958uWZSzdlvMU3D1A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1428163775</pqid></control><display><type>article</type><title>Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Matsui, Takeshi ; Kang, Jong-Hon ; Nojima, Masanori ; Tomonari, Akiko ; Aoki, Hironori ; Yamazaki, Hajime ; Yane, Kei ; Tsuji, Kunihiko ; Andoh, Seisho ; Andoh, Sachiko ; Sakai, Hajime ; Maemori, Masayo ; Maguchi, Hiroyuki ; Tanaka, Yasuhito</creator><creatorcontrib>Matsui, Takeshi ; Kang, Jong-Hon ; Nojima, Masanori ; Tomonari, Akiko ; Aoki, Hironori ; Yamazaki, Hajime ; Yane, Kei ; Tsuji, Kunihiko ; Andoh, Seisho ; Andoh, Sachiko ; Sakai, Hajime ; Maemori, Masayo ; Maguchi, Hiroyuki ; Tanaka, Yasuhito</creatorcontrib><description>ABSTRACT
Despite increasing reports of hepatitis B virus (HBV) reactivation in hematological malignancies, its incidence, and risk factors are still obscure. The aim of this study was to clarify the frequency and risk factors of HBV reactivation in hepatitis B surface antigen (HBsAg) undetectable patients with malignant lymphoma or multiple myeloma, during or after chemotherapy. A total of 109 patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma were enrolled in this study. Anti‐hepatitis B surface (anti‐HBs) and anti‐hepatitis B core (anti‐HBc) were checked before treatment, and HBV DNA in sera was quantified monthly during and after chemotherapy. Out of 109 patients, 42 (38.5%) had anti‐HBs and 59 (54.1%) had anti‐HBc. Among the 59 anti‐HBc positive patients, four patients (4/59, 6.8%) showed HBV reactivation during 20.5 median follow‐up months. In all four patients with HBV reactivation, peripheral lymphocyte counts before chemotherapy were lower than those without HBV reactivation (P = 0.033). HBV reactivation occurred during and after chemotherapy containing rituximab for non‐Hodgkin lymphoma. Four patients, who had HBV reactivation, did not develop de novo hepatitis due to HBV reactivation and were able to undergo chemotherapy against malignant lymphoma as scheduled. Monitoring of HBV DNA in sera is useful for the early diagnosis of HBV reactivation, and preemptive therapy is an useful alternative to prevent hepatitis due to HBV reactivation. Patients must be monitored periodically for HBV‐DNA levels during and after chemotherapy. J Med. Virol. 85:1900–1906, 2013. © 2013 Wiley Periodicals, Inc.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.23694</identifier><identifier>PMID: 23926082</identifier><identifier>CODEN: JMVIDB</identifier><language>eng</language><publisher>Hoboken, NJ: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinogenesis, carcinogens and anticarcinogens ; Cell number ; chemotherapy ; DNA, Viral - blood ; Female ; Fundamental and applied biological sciences. Psychology ; Hepatitis B - chemically induced ; Hepatitis B Antibodies - blood ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus ; Hepatitis B virus - physiology ; Human viral diseases ; Humans ; Infectious diseases ; lymphocyte ; Lymphoma - complications ; Lymphoma - drug therapy ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Miscellaneous ; Multiple Myeloma - complications ; Multiple Myeloma - drug therapy ; reactivation ; Tumors ; Viral diseases ; Viral Load ; Virology ; Virus Activation - drug effects ; Viruses ; Young Adult</subject><ispartof>Journal of medical virology, 2013-11, Vol.85 (11), p.1900-1906</ispartof><rights>2013 Wiley Periodicals, Inc.</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4544-a63a9900b08d1487d821162d350c8e434b4718a24e60beee6399b1553863196e3</citedby><cites>FETCH-LOGICAL-c4544-a63a9900b08d1487d821162d350c8e434b4718a24e60beee6399b1553863196e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.23694$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.23694$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27720226$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23926082$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsui, Takeshi</creatorcontrib><creatorcontrib>Kang, Jong-Hon</creatorcontrib><creatorcontrib>Nojima, Masanori</creatorcontrib><creatorcontrib>Tomonari, Akiko</creatorcontrib><creatorcontrib>Aoki, Hironori</creatorcontrib><creatorcontrib>Yamazaki, Hajime</creatorcontrib><creatorcontrib>Yane, Kei</creatorcontrib><creatorcontrib>Tsuji, Kunihiko</creatorcontrib><creatorcontrib>Andoh, Seisho</creatorcontrib><creatorcontrib>Andoh, Sachiko</creatorcontrib><creatorcontrib>Sakai, Hajime</creatorcontrib><creatorcontrib>Maemori, Masayo</creatorcontrib><creatorcontrib>Maguchi, Hiroyuki</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><title>Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma</title><title>Journal of medical virology</title><addtitle>J. Med. Virol</addtitle><description>ABSTRACT
Despite increasing reports of hepatitis B virus (HBV) reactivation in hematological malignancies, its incidence, and risk factors are still obscure. The aim of this study was to clarify the frequency and risk factors of HBV reactivation in hepatitis B surface antigen (HBsAg) undetectable patients with malignant lymphoma or multiple myeloma, during or after chemotherapy. A total of 109 patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma were enrolled in this study. Anti‐hepatitis B surface (anti‐HBs) and anti‐hepatitis B core (anti‐HBc) were checked before treatment, and HBV DNA in sera was quantified monthly during and after chemotherapy. Out of 109 patients, 42 (38.5%) had anti‐HBs and 59 (54.1%) had anti‐HBc. Among the 59 anti‐HBc positive patients, four patients (4/59, 6.8%) showed HBV reactivation during 20.5 median follow‐up months. In all four patients with HBV reactivation, peripheral lymphocyte counts before chemotherapy were lower than those without HBV reactivation (P = 0.033). HBV reactivation occurred during and after chemotherapy containing rituximab for non‐Hodgkin lymphoma. Four patients, who had HBV reactivation, did not develop de novo hepatitis due to HBV reactivation and were able to undergo chemotherapy against malignant lymphoma as scheduled. Monitoring of HBV DNA in sera is useful for the early diagnosis of HBV reactivation, and preemptive therapy is an useful alternative to prevent hepatitis due to HBV reactivation. Patients must be monitored periodically for HBV‐DNA levels during and after chemotherapy. J Med. Virol. 85:1900–1906, 2013. © 2013 Wiley Periodicals, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinogenesis, carcinogens and anticarcinogens</subject><subject>Cell number</subject><subject>chemotherapy</subject><subject>DNA, Viral - blood</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hepatitis B - chemically induced</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - physiology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>lymphocyte</subject><subject>Lymphoma - complications</subject><subject>Lymphoma - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Multiple Myeloma - complications</subject><subject>Multiple Myeloma - drug therapy</subject><subject>reactivation</subject><subject>Tumors</subject><subject>Viral diseases</subject><subject>Viral Load</subject><subject>Virology</subject><subject>Virus Activation - drug effects</subject><subject>Viruses</subject><subject>Young Adult</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0c1u1DAQB_AIgei2cOAFkCWEBIe0_ooTH7sVbUEtSFDo0XKSya6XJA62syVvwGPj_WiRkJA42Rr9ZsbWP0leEHxMMKYnq259TJmQ_FEyI1iKVOKcPE5mmHCRCkGyg-TQ-xXGuJCUPk0OKJNU4ILOkl-fQVfBrHUwtke2QUsY4j0Yj-ZobdzokenRpgR98OjOhCUa-xoCVEGXLaDLuT9dbEtuYU2_QNUSOhuW4PQwocY61OnWLHrdB9RO3bC0nUab6tgGM8QB3QRtrD1LnjS69fB8fx4lX8_f3ZxdplefLt6fnV6lFc84T7VgWkqMS1zUhBd5XVBCBK1ZhqsCOOMlz0mhKQeBSwAQTMqSZBkrBCNSADtK3uzmDs7-GMEH1RlfQdvqHuzoFYkzMMM5l_9BaZHnlJIs0ld_0ZUdXR8_slVEsDzfqLc7VTnrvYNGDc502k2KYLVJUsUk1TbJaF_uJ45lB_WDvI8ugtd7oH2l28bpvjL-j4svw5SK6E527s60MP17o_pw_e1-dbrrMD7Az4cO7b4rkbM8U7cfLxSe3958uWZSzdlvMU3D1A</recordid><startdate>201311</startdate><enddate>201311</enddate><creator>Matsui, Takeshi</creator><creator>Kang, Jong-Hon</creator><creator>Nojima, Masanori</creator><creator>Tomonari, Akiko</creator><creator>Aoki, Hironori</creator><creator>Yamazaki, Hajime</creator><creator>Yane, Kei</creator><creator>Tsuji, Kunihiko</creator><creator>Andoh, Seisho</creator><creator>Andoh, Sachiko</creator><creator>Sakai, Hajime</creator><creator>Maemori, Masayo</creator><creator>Maguchi, Hiroyuki</creator><creator>Tanaka, Yasuhito</creator><general>Blackwell Publishing Ltd</general><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201311</creationdate><title>Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma</title><author>Matsui, Takeshi ; Kang, Jong-Hon ; Nojima, Masanori ; Tomonari, Akiko ; Aoki, Hironori ; Yamazaki, Hajime ; Yane, Kei ; Tsuji, Kunihiko ; Andoh, Seisho ; Andoh, Sachiko ; Sakai, Hajime ; Maemori, Masayo ; Maguchi, Hiroyuki ; Tanaka, Yasuhito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4544-a63a9900b08d1487d821162d350c8e434b4718a24e60beee6399b1553863196e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinogenesis, carcinogens and anticarcinogens</topic><topic>Cell number</topic><topic>chemotherapy</topic><topic>DNA, Viral - blood</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hepatitis B - chemically induced</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - physiology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>lymphocyte</topic><topic>Lymphoma - complications</topic><topic>Lymphoma - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Multiple Myeloma - complications</topic><topic>Multiple Myeloma - drug therapy</topic><topic>reactivation</topic><topic>Tumors</topic><topic>Viral diseases</topic><topic>Viral Load</topic><topic>Virology</topic><topic>Virus Activation - drug effects</topic><topic>Viruses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsui, Takeshi</creatorcontrib><creatorcontrib>Kang, Jong-Hon</creatorcontrib><creatorcontrib>Nojima, Masanori</creatorcontrib><creatorcontrib>Tomonari, Akiko</creatorcontrib><creatorcontrib>Aoki, Hironori</creatorcontrib><creatorcontrib>Yamazaki, Hajime</creatorcontrib><creatorcontrib>Yane, Kei</creatorcontrib><creatorcontrib>Tsuji, Kunihiko</creatorcontrib><creatorcontrib>Andoh, Seisho</creatorcontrib><creatorcontrib>Andoh, Sachiko</creatorcontrib><creatorcontrib>Sakai, Hajime</creatorcontrib><creatorcontrib>Maemori, Masayo</creatorcontrib><creatorcontrib>Maguchi, Hiroyuki</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsui, Takeshi</au><au>Kang, Jong-Hon</au><au>Nojima, Masanori</au><au>Tomonari, Akiko</au><au>Aoki, Hironori</au><au>Yamazaki, Hajime</au><au>Yane, Kei</au><au>Tsuji, Kunihiko</au><au>Andoh, Seisho</au><au>Andoh, Sachiko</au><au>Sakai, Hajime</au><au>Maemori, Masayo</au><au>Maguchi, Hiroyuki</au><au>Tanaka, Yasuhito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J. Med. Virol</addtitle><date>2013-11</date><risdate>2013</risdate><volume>85</volume><issue>11</issue><spage>1900</spage><epage>1906</epage><pages>1900-1906</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><coden>JMVIDB</coden><abstract>ABSTRACT
Despite increasing reports of hepatitis B virus (HBV) reactivation in hematological malignancies, its incidence, and risk factors are still obscure. The aim of this study was to clarify the frequency and risk factors of HBV reactivation in hepatitis B surface antigen (HBsAg) undetectable patients with malignant lymphoma or multiple myeloma, during or after chemotherapy. A total of 109 patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma were enrolled in this study. Anti‐hepatitis B surface (anti‐HBs) and anti‐hepatitis B core (anti‐HBc) were checked before treatment, and HBV DNA in sera was quantified monthly during and after chemotherapy. Out of 109 patients, 42 (38.5%) had anti‐HBs and 59 (54.1%) had anti‐HBc. Among the 59 anti‐HBc positive patients, four patients (4/59, 6.8%) showed HBV reactivation during 20.5 median follow‐up months. In all four patients with HBV reactivation, peripheral lymphocyte counts before chemotherapy were lower than those without HBV reactivation (P = 0.033). HBV reactivation occurred during and after chemotherapy containing rituximab for non‐Hodgkin lymphoma. Four patients, who had HBV reactivation, did not develop de novo hepatitis due to HBV reactivation and were able to undergo chemotherapy against malignant lymphoma as scheduled. Monitoring of HBV DNA in sera is useful for the early diagnosis of HBV reactivation, and preemptive therapy is an useful alternative to prevent hepatitis due to HBV reactivation. Patients must be monitored periodically for HBV‐DNA levels during and after chemotherapy. J Med. Virol. 85:1900–1906, 2013. © 2013 Wiley Periodicals, Inc.</abstract><cop>Hoboken, NJ</cop><pub>Blackwell Publishing Ltd</pub><pmid>23926082</pmid><doi>10.1002/jmv.23694</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2013-11, Vol.85 (11), p.1900-1906 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1434030749 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinogenesis, carcinogens and anticarcinogens Cell number chemotherapy DNA, Viral - blood Female Fundamental and applied biological sciences. Psychology Hepatitis B - chemically induced Hepatitis B Antibodies - blood Hepatitis B Surface Antigens - blood Hepatitis B virus Hepatitis B virus - physiology Human viral diseases Humans Infectious diseases lymphocyte Lymphoma - complications Lymphoma - drug therapy Male Medical sciences Microbiology Middle Aged Miscellaneous Multiple Myeloma - complications Multiple Myeloma - drug therapy reactivation Tumors Viral diseases Viral Load Virology Virus Activation - drug effects Viruses Young Adult |
| title | Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T15%3A59%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reactivation%20of%20hepatitis%20B%20virus%20in%20patients%20with%20undetectable%20HBsAg%20undergoing%20chemotherapy%20for%20malignant%20lymphoma%20or%20multiple%20myeloma&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Matsui,%20Takeshi&rft.date=2013-11&rft.volume=85&rft.issue=11&rft.spage=1900&rft.epage=1906&rft.pages=1900-1906&rft.issn=0146-6615&rft.eissn=1096-9071&rft.coden=JMVIDB&rft_id=info:doi/10.1002/jmv.23694&rft_dat=%3Cproquest_cross%3E3055737051%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1428163775&rft_id=info:pmid/23926082&rfr_iscdi=true |